A WHO Guideline Development Group of international experts in the British Medical Journal (BMJ) BMJ said that almost all well-informed patients would not choose to receive sotrovimab or casirivimab-imdevimab.
Ad Blocker Enabled!
Ad Blocker Enabled!
Our website is made possible by displaying online advertisements to our visitors. Please support us by disabling your Ad Blocker.